Remove Resources Bioreactors
article thumbnail

Biologics driving continuous bioprocessing market expansion

European Pharmaceutical Review

With a wider focus on sustainability in the industry, continuous bioprocessing aligns with these goals due to its ability to require less resources when compared to batch processing, the research stated. These advancements “aim to optimise productivity, increase yield, and enhance product quality while reducing overall production costs.”

article thumbnail

Single-use bioprocessing market to value $84.14bn by 2032

European Pharmaceutical Review

Could centrifugal bioreactor accelerate cell-therapy manufacturing? This can be particularly beneficial for small and mid-sized manufacturers who may have limited resources, the author shared.

78
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Understanding Large Molecule Drug Development: From Biologics to Market

Impact Pharmaceutical Services

Upstream processing advancements encompass fed-batch processes , improved cell culture media, advanced feeding strategies, and tailored bioreactor control. Regulators will oversee the process through clinical trials and commercialization and are valuable resources themselves.

article thumbnail

Personalised culture media solutions support timely biopharmaceutical manufacturing

European Pharmaceutical Review

Lastly, if capacity or resources are the limiting factors, full-service media development and testing can be conducted at FUJIFILM Irvine Scientific facilities. Finally, the media can be optimised for culture in bioreactors, with the goal of identifying several candidates for confirmation at the client’s site.

article thumbnail

2022 ISPE Biotechnology Conference: Ongoing Growth & Development

ISPE

He presented “Advancing the Manufacturing of Complex Biologic Products” and discussed the potential of advanced manufacturing, case studies in COVID-19 and individual gene therapy, and resources from the FDA for product developers. Marks described some of the successes and challenges of the vaccine production in response to COVID-19.

article thumbnail

Inside the EASE Training Center: Where Hands-On Learning Meets Industry Excellence

ISPE

In 2023, ISPE successfully launched two pilot training events at EASE.

article thumbnail

USP/BIOPHORUM Workshop on Continuous Manufacturing of Biologics

ISPE

8 For example, this could be the filling of a bioreactor with growth media, the collection of eluate eluted from a capture chromatography step, exchanging the buffer of the final bulk drug substance, or flushing a collection tank with cleaning solution following a manufacturing run. 1 , 2 , 3 There are also barriers to the adoption of BCM.

FDA 52